Gülhan ÜNLÜ VARDAR, Mehmet ÜNLÜ, Aysel YAĞMUROĞLU, Dilara YILDIRIM

Klinik örneklerden soyutlanan escherıchıa colı ve klebsıella pneumonıae suşlarına tigesiklin etkinliği

Tigesiklin, yeni sınıf antibiyotiklerden olan glisilsiklinlerin ilk ticari üyesidir. Glisilsiklinler etkili Gram pozitif ve Gram negatif aktiviteyi olanaklı kılan yapısal değişiklikle tetrasiklin antibiyotiklerin türevidir. Bu çalışmada, klinik örneklerden soyutlanan 100 Escherichia coli ve 100 Klebsiella pneumoniae suşunun tigesikline direnci minimum inhibisyon konsan-trasyon (MİK) yöntemi ile araştırılmıştır. Tigesiklinin MİK50 ve MİK90 değerleri E.coli suşları için 0.25 µg/ml ve 0.5 µg/ml, K.pneumoniae suşları için 0.5 µg/ml ve 1.0 µg/ml olarak saptanmıştır. Çalışmamızda elde edilen bulgular, tigesiklinin hem E.coli hem de K.pneumoniae suşlarına karşı güçlü antibakteriyel aktiviteye sahip olduğunu göstermiştir.

Efficacy of tigecycline to escherichia coli and klebsiella pneumoniae strains İsolated from clinical specimens

Tigecycline is the first commercially available member of the glycylcyclines, a new class of antimicrobial agents. The glycylcyclines are derivatives of the tetracycline antibiotics, with structural modifications that allow for potent Gram-positive and Gram-negative activity. In this study, tigecycline resistance of 100 Escherichia coli and 100 Klebsiella pneumoniae strains isolated from clinical specimens was investigated using minimum inhibitory concentration (MIC) method. MIC50 and MIC90 values for tigecycline were determined as 0.25 µg/ml and 0.5 µg/ml for E.coli strains and as 0.5 µg/ml and 1.0 µg/ml for K.pneumoniae strains, respectively. These results demonstrate that tigecycline appears to have a strong antibacterial activity against both E.coli and K.pneumoniae strains.

PDF

___

1. Altındiş M, Şafak B, Demirdal T, Çetinkaya Z, Aktepe OC: Kan kültürlerinden izole edilen etkenlerde tigesiklin duyarlılığı, ANKEM Derg 2007;21(3):171-4.
2. Arslan U, Işık F, Tuncer İ: Klinik örneklerden soyutlanan Klebsiella pneumoniae suşlarında tigesiklinin in-vitro aktivitesi, ANKEM Derg 2006;20(4):199-201.
3. Biedenbach DJ, Beach ML, Jones RN: In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extendedspectrum beta-lactamases, Diagn Microbiol Infect Dis 2001;40(4):173-7.
4. Bouchillon SK, Hoban DJ, Johnson BM et al: In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002, Diagn Microbiol Infect Dis 2005;51(4):291-5.
5. Bradford PA: Tigecycline: A first in class tygecycline, Clin Microbiol Newsletter 2004;26(21):163-8.
6. Clinical and Laboratory Standards Institute (CLSI) (Gür D: Çeviri editörü): Antimikrobik Duyarlılık Testleri İçin Uygulama Standartları, Onsekizinci Bilgi Eki, M100-S18, Türk Mikrobiyoloji Cemiyeti Yayını, İstanbul (2008).
7. Çalık N, Akova M: Tigesiklin, ANKEM Derg 2007;21(Ek 2):29-33.
8. Fluit AC, Florijn A, Verhoef J, Milatovic D: Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline, J Antimicrob Chemother 2005;49(4):1636-8.
9. Fritsche TR, Sader HS, Stilwell MG, Dowzicky MJ, Jones RN: Antimicrobial activity of tigecycline tested against organisms causing communityacquired respiratory tract infection and nosocomial pneumonia, Diagn Microbiol Infect Dis 2005;52(3):187-93.
10. Fritsche TR, Sader HS, Stilwell MG, Dowzicky MJ, Jones RN: Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004), Diagn Microbiol Infect Dis 2005;52(3):195-201.
11. Gales AC, Sader HS, Fritsche TR: Tigecycline activity tested against 11808 bacterial pathogens recently collected from US medical centers, Diagn Microbiol Infect Dis 2008;60(4):421-7.
12. Hoban DJ, Bouchillon SK, Johnson BM, Johnson JL, Dowzicky MJ: Tigecycline Evaluation and Surveillance Trial (TEST Program) Group; In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global tigecycline evaluation and surveillance trial (TEST Program, 2004), Diagn Microbiol Infect Dis 2005;52(3):215-27.
13. Karaoğlan İ, Zer Y, Namıduru M: GSBL pozitif Escherichia coli ve Klebsiella pneumoniae suşlarında tigesiklinin in-vitro etkinliği, ANKEM Derg 2008;22(2):69-71.
14. Korten V, Soyletir G, Leblebicioglu H, Usluer G, Dündar D: In vitro activity of tigecycline against pathogens from Turkey - TEST Program 2006, Int J Antimicrob Agents 2007;29(Suppl 2):S517.
15. Livermore DM: Tigecycline: what is it, and where should it be used?, J Antimicrob Chemother 2005;56(4):611-4.
16. Milatovic D, Schmitz FJ, Verhoef J, Fluit, AC: Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacte-rial isolates, J Antimicrob Chemother 2003;47(1):400-4.
17. Noskin GA: Tigecycline: A new glycylcycline for treatment of serous infections, Clin Infect Dis 2005;41(Suppl 5):303-14.
18. Pankey GA: Tigecycline, J Antimicrob Chemother 2005;56(3):470-80.
19. Petersen PJ, Jacobus NV,Weiss WJ, Sum PE, Testa RT: In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936), Antimicrob Agents Chemother 1999;43(4):738-44.
20. Sader HS, Jones RN, Dowzicky MJ, Fritsche TR: Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit, Diagn Microbiol Infect Dis 2005;52(3):203-8.
21. Sader HS, Jones RN, Stilwell MG, Dowzicky MJ, Fritsche TR: Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents, Diagn Microbiol Infect Dis 2005;52(3):181-6.
22. Souli M, Kontopidou FV, Koratzanis E et al: In vitro activity of tigecycline against multiple-drugresistant, including pan-resistant, Gram-negative and Gram-positive clinical isolates from Greek Hospitals, Antimicrob Agents Chemother 2006;50(9):3166-9.
23. Ulusoy S: Tigesiklin, ANKEM Derg 2006;20(Ek 2):117-9.
24. Wyeth Pharmaceuticals Inc.: Tygacil Product Insert, June 2005, Philadelphia (PA), http://www. tygacil.com.